TIGIT and acute myeloid leukemia: The direct in vitro K562 cell killing assay showed that TIGIT+ NK cells from all four patients uniformly had lower killing activity than their corresponding TIGIT− NK cells, which demonstrated the inhibitory effect of TIGIT expression on NK cell-killing function in CBF-AML.